Engineering Research Center of Modern Preparation Technology of TCM, Ministry of Education, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Engineering Research Center of Modern Preparation Technology of TCM, Ministry of Education, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Chin J Nat Med. 2021 Mar;19(3):181-187. doi: 10.1016/S1875-5364(21)60019-5.
Rhododendron molle G. Don is first recorded in Shengnong's Herbal Classic, and its fruits, which are termed as Liuzhouzi, are often used to treat rheumatoid arthritis in Chinese folk. During our ongoing investigation to develop a safer and potential new arthritis therapy, a process for the preparation of diterpenoid fraction from Rhododendron mollefruits was established. In order to evaluate the main components and the anti-rheumatoid arthritis effect of the diterpenoid fraction, phytochemical and pharmacological experiments were used. As the result, the main components of diterpenoid fraction were identified as rhodojaponin III (1), rhodojaponin VI (2), 2-O-methylrhodojaponin (3), and 5'-β-D-glucopyranosy-loxyjasmonic acid (4). These four components constitute greater than 95% of diterpenoid fraction using area normalization method of HPLC-ELSD. The results of CIA rat experiment showed that high dose of diterpenoid fraction (0.6 mg·kg·d) significantly alleviated the symptoms of rheumatoid arthritis, similar to tripterygium polyglycosides, an effective RA therapy. Preliminary mechanism studies indicated that diterpenoid fraction significantly inhibited the abnormal proliferation of T and B lymphocytes, and remarkably reduced the levels of pro-inflammatory cytokines IL-6, IL-1β and TNF-α. Overall, our findings may provide a more effective and safe alternative treatment for RA using common clinical Chinese medicines like tripterygium polyglycosides.
密枝杜鹃最早记载于《神农本草经》,其果实被称为“瘤果杜鹃”,民间常用于治疗类风湿关节炎。在我们正在进行的开发更安全、更有潜力的新型关节炎治疗方法的研究中,建立了从密枝杜鹃果实中制备二萜类化合物部分的方法。为了评估二萜类化合物部分的主要成分和抗类风湿关节炎作用,进行了植物化学和药理学实验。结果表明,二萜类化合物部分的主要成分鉴定为密枝杜鹃苷 III(1)、密枝杜鹃苷 VI(2)、2-O-甲基密枝杜鹃苷(3)和 5'-β-D-吡喃葡萄糖氧基茉莉酸(4)。这四个成分占二萜类化合物部分的 95%以上,采用 HPLC-ELSD 的面积归一化法。CIA 大鼠实验结果表明,高剂量二萜类化合物部分(0.6mg·kg·d)显著缓解了类风湿关节炎的症状,与雷公藤多苷有效治疗 RA 相似。初步机制研究表明,二萜类化合物部分显著抑制 T 和 B 淋巴细胞的异常增殖,显著降低促炎细胞因子 IL-6、IL-1β 和 TNF-α 的水平。总之,我们的研究结果可能为使用雷公藤多苷等常见临床中药为 RA 提供更有效和安全的替代治疗方法。
Zhongguo Zhong Yao Za Zhi. 2023-11
Chin J Nat Med. 2018-6
Front Pharmacol. 2024-10-8
Evid Based Complement Alternat Med. 2022-3-25